Track topics on Twitter Track topics that are important to you
TORONTO, ON / ACCESSWIRE / May 9, 2019 / GeneNews Limited (TSX: GEN) ("GeneNews" or the "Company"), a life sciences company specializing in blood-based biomarker tests for early cancer detection, has launched the company's first awareness campaign on prostate cancer. The campaign uses Gary the Prostate to explore prostate cancer symptoms, tests and treatments.
"We wanted an approach to get people talking more openly about prostate health and conditions that affect the prostate," said James Howard-Tripp, CEO of GeneNews. "Gary allows us to do this in a relatable and engaging way. Many people feel embarrassed to talk about prostate cancer or even know what the prostate looks like or what it does. This is a way to start the conversation and create awareness."
According to the American Cancer Society (ACS), other than skin cancer, prostate cancer is the most common cancer in American men. The ACS estimates that in 2019 there will be approximately 174,650 new cases of prostate cancer and 31,620 deaths. About 1 man in 9 will be diagnosed with prostate cancer during his lifetime. Prostate cancer develops mainly in older men and in African-American men. (1)
Learn More About Gary's Campaign at www.mycancerrisk.info/Gary
Watch Gary's Campaign Kick-Off at the Link Below
GeneNews is dedicated to developing and commercializing innovative solutions for early cancer detection. Our mission is to provide advanced diagnostics that can help physicians identify cancer in their patients at the earliest possible stage (Stage 0) when it is the most curable. As early pioneers in the liquid biopsy space, GeneNews developed one of the first blood-based biomarker tests for the early identification of Colorectal Cancer. ColonSentry® uses the company's proprietary Sentinel Principle technology which is based on the scientific observation that circulating blood reflects, in a detectable way, what is occurring throughout the body. Today, more than 100,000 patients in the U.S. have benefited from the ColonSentry test. GeneNews' next generation test, Aristotle®, will use this proven technology to test for ten cancers from a single blood sample. In addition to building a pipeline of products for early cancer detection, GeneNews operates a CAP accredited and CLIA certified, clinical reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. www.GeneNews.com.
James R. Howard-Tripp
Chairman & CEO
Tel. (905) 209-2030
SOURCE: GeneNews Limited
Benign Prostatic Hyperplasia (BPH)
An enlarged prostate (benign prostatic enlargement (BPE) or benign prostatic hyperplasia (BPH)) is common in men after the age of about 50. Having an enlarged prostate does not mean you have cancer. In some cases, an enlarged prostate can cause the ...
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...